register

Digital & Innovation

Australian-first research uses AI to diagnose paediatric eye disease

Health Industry Hub | September 7, 2020 |

Digital & Innovation: An Australian-first study funded by the Children’s Hospital Foundation is set to use artificial intelligence (AI) to diagnose a potentially devastating cause of childhood blindness automatically and accurately.

The results could reduce blindness in babies with plus disease, a severe form of retinopathy of prematurity (ROP) which is caused by abnormal development of retinal blood vessels in premature infants.

ROP is a sight-threatening disease affecting more than 50,000 children across the globe and approximately 3,000 in Australia, and it remains one of the leading causes of infant blindness due to challenges with diagnosis and screening.

Blindness caused by ROP is preventable if it is detected and treated early, and this research aims to improve ROP screening for infants in remote and regional areas where a specialist ophthalmologist is not readily available.

Queensland Children’s Hospital Director of Ophthalmology, Dr. Shuan Dai, who is leading the two-year study, will receive $100,000 of funding thanks to our valued corporate sponsor, The Lott by Golden Casket.

“In Australia, almost half of premature infants born less than 31 weeks, or under 1250g, were diagnosed with ROP, which is a staggering statistic, and the incidence of this has not improved in the past decade,” Dr. Dai said.

“There’s a huge shortage of ophthalmologists who are trained and able to diagnose ROP, particularly in those regional and rural areas, creating inequity in care, and leading to too many children going undiagnosed timely.”

“No child should ever have to live without sight, so it is my hope that we can refine this artificial intelligence algorithm, allowing children in regional and remote areas of Queensland to have the same health opportunities as those based in metropolitan areas, preventing avoidable blindness through early diagnosis and equitable access to treatment,” Dr. Dai added.


News & Trends - Pharmaceuticals

Clinicians unveil Novartis and BMS practice-changing trial results

Clinicians unveil Novartis and BMS practice-changing trial results

Health Industry Hub | June 24, 2024 |

Pharma News: Australia, known for its alarming melanoma rates, witnesses one person diagnosed with the disease every 30 minutes, and […]

More


News & Trends - Pharmaceuticals

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Health Industry Hub | June 24, 2024 |

Pharma News: Heart failure is a significant health concern in Australia, affecting approximately half a million people, with over 67,000 […]

More


News & Trends - MedTech & Diagnostics

Cardiologists mark Australian first with Boston Scientific's intracoronary imaging system

Cardiologists mark Australian first with Boston Scientific’s intracoronary imaging system

Health Industry Hub | June 24, 2024 |

MedTech & Diagnostics News: Percutaneous coronary intervention (PCI) has faced substantial complications and failure rates, despite advances in medical devices […]

More


Leadership & Management

AbbVie New Zealand welcomes new leadership amid global moves

AbbVie New Zealand welcomes new leadership amid global moves

Health Industry Hub | June 24, 2024 |

Leadership & Management: In line with its global talent development plan, AbbVie has announced a significant change in leadership for […]

More


This content is copyright protected. Please subscribe to gain access.